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Abstract
Background & Aims: Hepatic iron accumulation due to altered trafficking is frequent in patients with nonalcoholic fatty liver
disease (NAFLD), and is associated with more severe liver damage and hepatocellular carcinoma. The p.Ala736Val TMPRSS6
variant influences iron metabolism regulating the transcription of the hepatic hormone hepcidin, but its role in the
pathogenesis of iron overload disorders is controversial. Aim of this study was to evaluate the whether the TMPRSS6
p.Ala736Val variant influences hepatic iron accumulation in a well-characterized series of Italian patients with histological
NAFLD.
Methods: 216 patients with histological NAFLD. TMPRSS6 and HFE variants were assessed by allele specific PCR, liver
histology by the NAFLD activity score and Perls’ staining for iron.
Results: Homozygosity for the p.736Val allele previously linked to higher hepcidin did not influence transferrin saturation
(TS), but was associated with lower hepatic iron stores (p = 0.01), and ferritin levels (median 223 IQR 102–449 vs. 308 IQR
141–618 ng/ml; p = 0.01). Homozygosity for TMPRSS6 p.736Val was nearly associated with lower ballooning (p = 0.05),
reflecting hepatocellular damage related to oxidative stress. The influence of TMPRSS6 on hepatic iron accumulation was
more marked in patients negative for HFE genotypes predisposing to iron overload (p.Cys282Tyr + and p.His63Asp +/+;
p = 0.01), and the p.736Val variant was negatively associated with hepatic iron accumulation independently of age, gender,
HFE genotype, and beta-thalassemia trait (OR 0.59, 0.39–0.88).
Conclusions: The p.Ala736Val TMPRSS6 variant influences secondary hepatic iron accumulation in patients with NAFLD.
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Introduction
Liver fat deposition related to systemic insulin resistance and the
metabolic syndrome defines nonalcoholic fatty liver disease
(NAFLD) [1,2]. In susceptible individuals NAFLD is associated
with oxidative hepatocellular damage, inflammation, and activa-
tion of fibrogenesis, i.e. non-alcoholic steatohepatitis (NASH)
[3,4], with potential progression towards cirrhosis and hepatocel-
lular carcinoma [5,6]. Due to the epidemic of obesity and the
metabolic syndrome, NAFLD is now the most frequent liver
disease and the leading cause of altered liver enzymes in Western
countries [7,8], and it is projected to become the leading cause of
end-stage liver disease and hepatocellular carcinoma.
Hyperferritinemia and mild iron overload are strongly associ-
ated with NAFLD [9,10,11,12,13,14,15], being detected in about
30% of unselected patients [11,16,17,18,19,20]. In patients with
steatosis, body iron stores have been linked to a heightened risk of
metabolic complications [21,22,23], faster progression of cardio-
vascular damage [24,25,26,27], more severe liver inflammation
and fibrosis [9,10,11,15,28,29,30], and hepatocellular carcinoma
[31]. In addition, iron depletion reduced insulin resistance and
indices of liver necrosis in controlled studies [15,17]. Differently
from genetic iron overload disorders [32], NAFLD and the
metabolic syndrome are characterized by preserved upregulation
of the iron hormone hepcidin [15,33], which inhibits iron
absorption and recycling by binding and inactivating the cellular
iron exporter Ferroportin-1 [34]. Therefore, the pathogenesis of
iron accumulation in NAFLD has been related to altered cellular
iron export associated with steatosis, hepatic inflammation, and IR
[15,35].
Genetic factors influencing the regulation of the iron hormone
hepcidin, such as mutations in the HFE gene of hereditary
hemochromatosis, contribute to the susceptibility to iron accumu-
lation in NAFLD [11,15,18]. We have also shown that beta-globin
mutations represent the best predictor of parenchymal iron
overload in Italian patients with NAFLD, and are associated with
a two-fold higher risk of severe fibrosis [12], linking iron overload
to progressive liver disease.
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The Trans-membrane protease serine 6 (TMPRSS6) gene encodes for
enzymes matriptase-2, which cleaves the membrane-bound
hemojuvelin, a bone morphogenetic protein (BMP) coreceptor
required for hepcidin expression in the liver, thereby decreasing
hepcidin transcription [36]. Rare loss-of-function mutations in
TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)
by upregulating hepcidin due to the inability to cleave hemojuvelin
[37], whereas common TMPRSS6 polymorphisms are a risk factor
for iron-deficiency anemia. The strongest association was observed
for TMPRSS6 rs855791 C.T polymorphism in exon 17, a
nonsynonymous substitution encoding for the p.Ala736Val variant
that reduces the ability of the enzyme to cleave hemojuvelin and
therefore to inhibit hepcidin transcription [38], thereby influenc-
ing transferrin saturation (TS), and erythropoiesis
[37,39,40,41,42]. We recently reported that the p.Ala736Val
variant influences the penetrance and expression of hereditary
hemochromatosis [43]. However, the relationship between
TMPRSS6 genotype and the expression of hemochromatosis is
still controversial, and no data are available on the effect on iron
overload disorders not related to hepcidin dysregulation.
Aim of this study was to evaluate the whether the TMPRSS6
p.Ala736Val variant influences hepatic iron accumulation in a
well-characterized series of Italian patients with histological
NAFLD.
Materials and Methods
Patients
We considered 216 out of 274 Italian patients (79%) with biopsy
proven NAFLD reported in a previous paper [12], without
phenotypically expressed hereditary hemochromatosis, whose
DNA samples and complete clinical data were available, and
who gave written informed consent. The clinical features of the
patients included are not significantly different from those of
subjects not included in this study (not shown). Other causes of
liver disease were excluded, including increased alcohol intake
(.30/20 g/day for M/F), as confirmed by at least one family
member and carboxydesialylated transferrin determination
(,1.5%), the p.Cys282Tyr +/+ HFE genotype typical of
hereditary hemochromatosis, hereditary iron overload due to
Ferroportin-1 mutations, alpha1-antitrypsin deficiency (PiZ/Z,
PiZ/S), chronic viral and autoimmune hepatitis, Wilson disease,
and celiac disease. BMI and metabolic parameters, including
glucose and lipid levels, ferritin, and liver enzymes (AST, ALT,
GGT), and evaluation of acquired causes of iron overload, were
determined in all patients. Serum hepcidin levels, available in a
subset of patients (n = 55), were determined as previously described
[44] for the evaluation of the relationship between iron and
vascular damage in the same cohort [24,27]. Hyperferritinemia
has been defined for values of serum ferritin greater than 240 ng/
ml in women and 320 ng/ml in men (upper reference value for the
normal population in our laboratory) [12].
We also considered 271 healthy blood donors with normal iron
parameters (serum ferritin and transferrin saturation (TS) at first
blood donation), liver enzymes (AST, ALT, GGT), and metabolic
parameters (glucose, triglycerides) as controls, all of Italian
ancestry (Milan area). The study was approved by the institutional
Review Board of the Fondazione Ca’ Granda IRCCS, and it has
been conducted according to the principles expressed in the
Declaration of Helsinki. All evaluated subjects signed an informed
consent. Demographic and clinical features of the subjects
included are shown in table 1.
Histological assessment
Tissue sections were stained with hematoxylin and eosin,
impregnated with silver for reticulin framework, and stained with
trichrome for collagen. One expert pathologist unaware of clinical
and genetic data reviewed all biopsies for fibrosis stage and the
presence and pattern of liver siderosis. The presence of NASH was
assessed according to Kleiner et al. [45]. The minimum biopsy size
was 1.7 cm and the number of portal areas 10. Histological re-
evaluation of liver siderosis was performed by one expert
pathologist according to Deugnier [46].
When detected, hepatic iron accumulation was defined as
hepatocellular or non-parenchymal according to the prevalent
distribution pattern of siderosis [12].
Genetic analysis
DNA was extracted from peripheral blood by the phenol-
chloroform method. Success rate in extracting DNA was 100% for
each study group. HFE genotype (p.Cys282Tyr and p.His63Asp
Table 1. Demographic, clinical, and genetic features of 216
Italian patients with NAFLD with available re-evaluation of
histological siderosis and of 271 healthy controls with normal
iron parameters, liver function tests, and metabolic
parameters.
NAFLD patients Healthy controls
Number 216 271
Sex F 49 (18) 56 (21)
Age years 49612* 45612
BMI Kg/m2 2764* 2663
Hb g/dl 1462 1462
Total cholesterol mg/dl 206640 193633
HDL cholesterol mg/dl 47614* 57613
Triglycerides mg/dl 151689* 88646
Glucose mg/dl 99624* 67633
HOMA-IR 4.163.2* 1.260.2
ALT UI/ml 54640* 2369
GGT UI/ml 72679* 21613
TS% 34612 3369
Ferritin ng/ml 286 {138–585} 37 {22–68}
Fibrosis stage F 2–4 38 (18) -
HFE genotype
p.Cys282Tyr/His63Asp 10 (5) 2 (1)
p.Cys282Tyr +/wt 15 (7) 7 (2)
p.His63Asp/His63Asp 9 (4) 9 (3)
p.His63Asp/wt 54 (25) 76 (28)
wt/wt 128 (59) 178 (66)
Beta-thalassemia trait 22 (10)* 0‘
TMPRSS6 p.Ala736Val
Ala/Ala 82 (38) 88 (32)
Ala/Val 101 (47) 137 (51)
Val/Val 33 (15) 46 (17)
(): % values; BMI: body mass index; Hb: hemoglobin concentration; TS%:
transferrin saturation %; wt: wild-type variant;
*p,0.05 vs. healthy controls;
‘beta-thalassemia trait was a criterium for exclusion from blood donation.
doi:10.1371/journal.pone.0048804.t001
TMPRSS6 in NAFLD
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variants), and the TMPRSS6 rs855791 C.T polymorphism,
(p.Ala736Val variant) were determined by sequence allele specific
PCR, as previously described [12,43]. Random samples were
confirmed by direct sequencing. Quality controls were performed
to verify the reproducibility of the results. Valid genotypic data
were obtained for 100% of subjects analyzed.
Statistical analysis
Values are expressed as means6SD or median {interquartile
range} according to distribution. Mean values were compared by
Anova or Wilcoxon (as required), frequencies by Chi-square test
and Cochrane-Armitage test for trend, when appropriate. The
association of the TMPRSS6 p.Ala736Val variant with iron
overload and the severity of liver disease was evaluated by logistic
regression analysis, considering as independent variables demo-
graphic and anthropometric features and genetic variables
significant at univariate analysis. P values were considered
significant when #0.05 (two-tailed). The sample size had .90%
power (p,0.05) of detecting 2-fold variation in risk of hepatic iron
accumulation. Analyses were carried out with JMP 6.0 statistical
analysis software (SAS Institute Inc, Cary, NC).
Results
Clinical and genetic features of patients and controls
As expected, patients with NAFLD had higher BMI, insulin
resistance, dyslipidemia, ferritin levels, and liver enzymes com-
pared to healthy controls (table 1). There was a nonsignificant
trend for an increased prevalence of the p.Cys282Tyr HFE
mutations in patients, whereas the prevalence of the beta-
thalassemia trait was significantly higher in patients than in
controls, but it represented and exclusion criterium for the control
group. The frequency distribution of the p.Ala736Val TMPRSS6
variant was in Hardy-Weinberg equilibrium and not significantly
different from that of healthy controls with normal iron
parameters (table 1; p = ns), suggesting that, as expected,
TMPRSS6 genotype is not a risk factor for NAFLD.
Effect of TMPRSS6 p.Ala736Val in patients with NAFLD
Clinical features of NAFLD patients subdivided according to
the p.Ala736Val TMPRSS6 status are shown in table 2. Homo-
zygosity for the p.736Val allele (henceforth 736V/V), previously
linked to higher hepcidin release, did not influence Hb levels.
However, in line with data observed in the general population,
736V/V patients without the beta-thalassemia trait had signifi-
cantly lower MCV values (table 2). The 736V/V status was
associated with lower ferritin levels (median 223 IQR 102–449 vs.
308 IQR 141–618 ng/ml; p = 0.01), but not with lower TS.
Supporting a negative association with iron accumulation,
736V/V was also associated with a lower prevalence of detectable
hepatic iron stores (p = 0.01).
In the 55 patients (16 Ala/Ala, 31 Ala/Val, 8 Val/Val) with
available hepcidin-25 measurement at the time of liver biopsy, the
p.Ala736Val variant was associated with an increasing prevalence
of high hepcidin (.3 nM, median value) with increasing number
of 736 V alleles, despite lower iron stores (p = 0.028 for trend;
figure 1A). Furthermore, H/F was higher in the 736Val positive
than in negative patients (p = 0.005; figure 1B). However, this
analysis is limited by lack of available data in the majority of
patients considered.
The 736V/V was associated with decreased prevalence of
severe hepatocellular ballooning (p = 0.05), reflecting hepatocellu-
lar damage related to oxidative stress, despite similar steatosis,
necroinflammation, and fibrosis stage (table 2).
Interaction between TMPRSS6 and HFE genotypes and
effect of the beta thalassemia trait on iron metabolism in
NAFLD
HFE genotypes at risk for iron overload (p.Cys282Tyr positive
and His63Asp/His63Asp, n = 34) were associated with higher TS
(42612 vs. 32612; p = 0.0004) and hepatic iron deposition (23/
34, 68% vs. 58/182, 32%; p = 0.0002), and with higher serum
ferritin (458 {240–622} vs. 237 {134–574} ng/ml; p = 0.08).
TMPRSS6 p.Ala736Val status influenced hepatic iron deposi-
tion in patients negative, but not in those positive for HFE
genotypes at risk for iron overload, whereas HFE genotypes at risk
influenced hepatic iron accumulation in patients positive for the
p.736Val TMPRSS6 variant (figure 2A). In contrast, p.Ala736Val
status influenced ferritin levels in both patients with and without
HFE genotypes at risk, although in opposite direction (figure 2B).
In patients without HFE genotypes at risk, concordantly with
decreased iron stores, the prevalence of hyperferritinemia was
lower in 736V/V subjects, whereas in the presence of HFE
genotypes at risk 736V/V was associated with increased ferritin.
TS was not influenced by TMPRSS6 genotype neither in patients
positive of negative for HFE genotypes at risk (not shown).
Besides with red cell parameters (MCV 6768 vs. 9065 fl,
p,0.0001; Hb 12.561.6 vs. 14.761.3 g/dl, p,0.0001), the beta-
thalassemia trait, detected in 22 patients (10%), was associated
with higher ferritin (531, 132–858 vs. 252, 131–568, p = 0.01), TS
(38610 vs. 33612%, p = 0.03), lower H/F (2, 1–12 vs. 7, 2–
186103, p = 0.019), and hepatic iron accumulation (15/23, 65%
vs. 66/193, 34%, p = 0.005).
Determinants of hepatic iron accumulation
The frequency distribution of genetic risk factors in patients
with and without hepatic iron accumulation is presented in
figure 3. The prevalence of beta-thalassemia trait and of HFE
genotypes at risk was higher, whereas that of 736V/V TMPRSS6
was lower in patients with hepatic iron (p,0.0001).
The clinical and genetic parameters associated with hepatic iron
accumulation at univariate analysis are presented in table 3. The
independent determinants of hepatic iron accumulation are
presented in table 4. Iron parameters were excluded from the
analysis in order to test the independent effect of genetic factors
after correction for demographic and anthropometric features.
The TMPRSS6 p.736Val allele was negatively associated with
hepatic iron accumulation independently of age, gender, the
presence of HFE genotypes at risk, and the beta-thalassemia trait
(OR 0.59, 95% confidence interval 0.39–0.88, per each p.736Val
allele).
Discussion
In this paper, we evaluated whether the TMPRSS6 p.Ala736Val
variant influencing hepcidin transcription and iron status in the
general population [38,39,40,41,47,48], affects hepatic iron
overload in patients with NAFLD. The study was prompted by
evidence indicating that iron overload unrelated to hepcidin
dysregulation is frequently observed in patients with NAFLD [15],
is favored by genetic factors [11,12], and is associated with the
severity of hepatic and vascular disease [11,14,29,49]. TMPRSS6
genotype has been shown to influence iron metabolism in animal
models of hereditary hemochromatosis and beta-thalassemia
[50,51], but the effect on iron overload in patients with
hemochromatosis is still controversial [43], and no data were
available for the effect of TMPRSS6 genotype in models of iron
overload where hepcidin upregulation is preserved [15,33].
TMPRSS6 in NAFLD
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In line with the experimental hypothesis, the results of the
present study suggest that the p.Ala736Val variant influences the
susceptibility to iron accumulation in NAFLD, even if, as
expected, is not a risk factor for NAFLD. Indeed, the p.736Val
‘‘high hepcidin’’ allele was associated with lower ferritin levels, and
most importantly with the absence of hepatic iron accumulation,
i.e. with direct evidence of iron overload. However, differently
from what was observed in the general population, TMPRSS6
genotype did not influence TS, which on the other hand was
modulated by HFE mutations and the beta-thalassemia trait.
Notably, the negative association with the presence of hepatic iron
accumulation was independent of demographic features, such as
Table 2. Clinical features of 216 Italian patients with NAFLD subdivided according to the p.Ala736Val TMPRSS6 status.
TMPRSS6 p.Ala736Val Ala/Ala Ala/Val Val/Val p value
Number 82 101 33
Sex F 12 (15) 18 (18) 8 (24) 0.48
Age years 49611 48612 48611 0.93
BMI Kg/m2 26.962.7 26.963.9 26.062.8 0.35
Hb g/dlu 14.761.2 14.761.3 14.661.5 0.81
MCVu 9064 9066 8865* 0.10
TS % 34616 33612 35614 0.62
Ferritin ng/ml 290 {141–590} 328 {135–628} 223 {102–449}* 0.08
Total cholesterol mg/dl 200639 202640 199644 0.92
HDL cholesterol mg/dl 46613 47615 43612 0.40
Triglycerides mg/dl 145682 156690 140677 0.55
Glucose mg/dl 97622 97629 96617 0.94
HOMA-IR 4.063.2 4.363.6 4.063.2 0.88
ALT UI/ml 49637 54644 58635 0.42
GGT UI/ml 72687 79684 76687 0.86
Hepatocellular iron positive 26 (32) 22 (22) 6 (18) 0.08
Nonparenchymal iron positive 31 (38) 30 (30) 7 (10) 0.06
Positive iron stores 39 (48) 33 (33) 9 (27) 0.01
Steatosis .33% 20 (24) 16 (16) 7 (21) 0.46
Necroinflammation score .1 4 (5) 2 (2) 1 (3) 0.80
Ballooning score .1 9 (11) 8 (8) 0 0.05
Fibrosis stage,1 17 (21) 16 (16) 5 (15) 0.38
(): % values; BMI: body mass index; Hb: hemoglobin concentration; MCV mean corpuscular volume;
uevaluated in cases negative for the beta-thalassemia trait (72 Ala/Ala, 91 Ala/Val, 31 Val/Val);
*p,0.05 for Val/Val vs. Ala/Ala and Ala/Val (recessive model).
doi:10.1371/journal.pone.0048804.t002
Figure 1. Effect of TMPRSS6 p.A736V genotype on hepcidin levels (hepcidin,3 nM, median value, panel A) and the hepcidin/ferritin
ratio (panel B) in 55 patients with NAFLD (25.5% of the whole series).
doi:10.1371/journal.pone.0048804.g001
TMPRSS6 in NAFLD
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age and gender, and of other genetic factors (HFE mutations and
the beta thalassemia trait). Although hepcidin was measured by
mass spectrometry in a minority of subjects (only about one
quarter), the available data suggest that the mechanism linking the
p.736Val allele to protection from iron overload is related to
increased serum hepcidin levels (despite lower iron stores), which is
consistent with data indicating that this genetic variant positively
influences hepcidin transcription [38]. It can be hypothesized that
the effect of the p.736 V variant on hepcidin levels is magnified in
NAFLD patients by the induction of hepcidin transcription due to
overweight, liver steatosis, and subclinical inflammation [15].
However, given the aforementioned limitations, these data should
be interpreted with caution. Therefore, the main results of the
present manuscript is that TMPRSS6 p.Ala736Val variant
influences iron accumulation even in secondary iron overload
disorders which are not caused by a deficit in the upregulation of
hepcidin in response to iron, such as hereditary hemochromatosis.
The TMPRSS6 p.Ala736Val variant may thus represent a modifier
of iron overload in other conditions, besides in NAFLD,
characterized by altered iron trafficking such as chronic inflam-
matory diseases, the anemia of chronic diseases, and possibly some
neurologic diseases characterized by altered iron compartmental-
ization [32].
Interestingly, the effect of TMPRSS6 on the presence of
detectable hepatic iron was more marked in subjects negative for
HFE genotypes predisposing to iron overload, suggesting that HFE
mutations may have a dominant effect at least in the NAFLD
setting, but the study was not powered enough to test the
interaction between these genetic factors.
An interesting collateral finding was that, as expected based on
the previous results, 736V/V homozygosity was associated with a
lower prevalence of hyperferritinemia in patients without HFE at
risk, but was paradoxically associated with higher ferritin levels
without altering hepatic iron stores in patients with HFE mutations
increasing iron absorption. These data suggest that the single
evaluation of traditional serum iron parameters may not be
sufficient to study the interaction between HFE and TMPRSS6 in
the regulation of iron metabolism. Indeed, HFE and TMPRSS6
Figure 2. Combined effect of the HFE and TMPRSS6 genotypes on iron status in 216 Italian patients with NAFLD. A) Prevalence of
detectable hepatic iron deposition B) Prevalence of increased ferritin levels (.320/240 ng/ml in M/F). p values are for trend across TMPRSS6
genotypes in patients carrying HFE genotypes at risk or not. * p,0.05 vs. HFE genotypes at risk.
doi:10.1371/journal.pone.0048804.g002
Figure 3. Frequency distribution of genetic factors influencing iron metabolism in patients with and without hepatic iron
accumulation. Patients positive for the beta-thalassemia trait were classified as ‘‘Beta-trait’’, next if negative for ‘‘Beta-trait’’ and positive for HFE
genotypes at risk as ‘‘HFE at risk’’, and among the remaining patients those homozygous for the 736V/V TMPSS6 as ‘‘736VV’’, and the rest as ‘‘none’’.
doi:10.1371/journal.pone.0048804.g003
TMPRSS6 in NAFLD
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genotypes influenced different iron parameters (TS and ferritin
respectively), and the phenotypes were modified when mutations
occurred together, suggesting that HFE and TMPRSS6 variants
alter iron trafficking by partially different mechanisms. It could be
speculated that the TMPRSS6 p.736Val variant promotes a shift in
iron balance towards macrophages and ferritin secretion by
facilitating hepcidin release and iron fluxes towards macrophages.
This would lead to an overestimation of iron stores, in particular in
subjects with HFE mutations predisposing to increased iron
absorption by mechanisms partially independent of hepcidin
[41]. This hypothesis should be taken into account when
evaluating the effect of TMPRSS6 on iron overload disorders,
leaving as the most reliable markers iron removed to depletion and
the direct assessment of hepatic iron.
Notwithstanding, in the overall series of patients the negative
association (with borderline significance) between the p.736Val
variant and the presence of detectable hepatic iron was paralleled
by decreased levels of hepatocellular ballooning, a typical
manifestation of oxidative stress in NAFLD [52], which is possibly
related to iron status. However, these associations, that need to be
confirmed in larger studies including patients from different
geographic areas, did not translate into increased severity of liver
fibrosis, possibly due to the limited number of subjects with
advanced liver disease included in this study.
Conclusions
In conclusion, the p.Ala736Val TMPRSS6 variant influences
hepatic iron accumulation in patients with NAFLD, likely by
influencing hepcidin levels, indicating that TMPRSS6 genotype
affects iron accumulation related to altered iron trafficking.
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